



Timothy Elliott
Executive Director and Associate General Counsel
Legal Department

January 14, 2015

VIA E-MAIL

Christopher J. Kirkpatrick
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, DC 20581

RE: CFTC Regulation §40.3 and CEA Section 5c(c). Voluntary Extension of Review Period for CME Submission No. 10-195 Regarding Standard and Poor's 500 Dividend Index Futures for Commission Review and Approval.

Dear Mr. Kirkpatrick:

In correspondence dated July 14, 2010, Chicago Mercantile Exchange Group ("CME" or "Exchange") voluntarily submitted S&P 500 Dividend Index futures for Commission review and approval per Section 5c(c) of the CEA and Regulation §40.3 thereunder.¹ The Commission responded via correspondence dated July 22, 2010, indicating that "[t]he proposed contract raises novel and complex issues and concerns ... [thus] in accordance with Commission Regulation 40.3(c), the 45-day Fast-Track review period has been extended, pursuant to the delegated authority of Commission Regulation 40.7(a), by 45 days until October 12, 2010." Subsequently, CME voluntarily consented to a further 90-day extension of the review period until January 10, 2011 via correspondence dated September 27, 2010, a second 90-day extension of the review period until April 10, 2011 via correspondence dated November 24, 2010, a third 90-day extension of the review period until July 9, 2011 via correspondence dated April 7, 2011, a fourth 90-day extension of the review period until October 7, 2011 via correspondence dated June 28, 2011, a fifth 180-day extension of the review period until April 4, 2012 via correspondence dated September 21, 2011, a sixth 180-day extension of the review period until October 1, 2012 via correspondence dated April 4, 2012, a seventh 180-day extension of the review period until March 30, 2013 via correspondence dated September 28, 2012, an eighth 180-day extension of the review period until September 26, 2013 via correspondence dated March 15, 2013, a ninth 30-day extension of the review period until October 26, 2013 via correspondence dated September 24, 2013, a tenth 30-day extension of the review period until November 25, 2013 via correspondence dated October 25, 2013, an eleventh 90-day extension of the review period until February 23, 2014 via correspondence dated November 22, 2013, a twelfth 30-day extension of the review period until March 25, 2014 via correspondence dated February 14, 2014, a thirteenth 60-day extension of the review period until May 24, 2014 via correspondence dated March 21, 2014, a fourteenth 90-day extension of the review period until August 22, 2014 via correspondence dated May 20, 2014, a fifteenth 90-day extension of the review period until November 20, 2014 via correspondence dated August 22, 2014, a sixteenth 30-day extension of the review period until December 19, 2014 via correspondence dated November 14, 2014, and a seventeenth 45-day extension of the review period until February 2, 2015 via correspondence dated December 4, 2014.

CME now voluntarily consents to a further 90-day extension of the review period until May 4, 2015. This extension is offered to provide the Commission with further opportunity to consider the complex issues and concerns raised as a result of our submission and in consultation with Commission staff.

¹ CME Submission #10-195

If you require any additional information regarding this action, please contact me at 312-466-7478 or via e-mail at Tim.Elliott@cmegroup.com.

Sincerely,

/s/ Tim Elliott
Executive Director and Associate General Counsel

cc: Mr. Vincent A. McGonagle